RxDoctor Payments Data

Mazen Elkurd, DO

Neurology · Dallas, TXNPI 1891180311

Payments from drug & device makers

$54,625in general payments, 2019–2025

Across 666 payments — averaging $82.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Abbott$15K
  • Merz Pharmaceuticals, LLC$5K
  • Kyowa Kirin, Inc.$4K
  • Acadia Pharmaceuticals Inc$2K
  • MDD US Operations, LLC$2K
  • plus $11K from 41 others

What the payments were for

  • Consulting fees$8,90816%
  • Speaking & faculty fees$10,01418%
  • Grants$15,00027%
  • Travel & lodging$5,54710%
  • Food & beverage$14,97727%
  • Education$1790%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,625 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$349,793
Medicare patients
426
Services billed
31,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa629$888,358
NuplazidPimavanserin Tartrate94$563,320
AustedoDeutetrabenazine23$312,967
IngrezzaValbenazine Tosylate14$130,876
GocovriAmantadine Hcl17$83,646
NourianzIstradefylline28$59,358
BotoxOnabotulinumtoxina40$51,977
UbrelvyUbrogepant23$33,063
InbrijaLevodopa14$29,362
Carbidopa-LevodopaCarbidopa/Levodopa506$23,110
OngentysOpicapone18$21,807
Rasagiline Mesylate67$11,862
XeominIncobotulinumtoxina11$11,059
Entacapone64$10,865
Carbidopa-Levodopa ErCarbidopa/Levodopa90$7,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$472$888,358629 claims
Acadia Pharmaceuticals IncNuplazid$2,295$563,32094 claims
Teva Pharmaceuticals USA, Inc.Austedo$573$312,96723 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$903$152,68332 claims
AbbVieBotox, Ubrelvy$1,604$85,04163 claims
MDD US Operations, LLCGocovri$1,615$83,64617 claims
Kyowa Kirin, Inc.Nourianz$3,593$59,35828 claims
Acorda Therapeutics, IncInbrija$123$29,36214 claims
Merz North America, Inc.Xeomin$40$11,05911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →